



🚀 Exclusive Investment Opportunity: Shape the Future of AI Medical Healthcare! 🚀

🌐 Introducing a **\$6 Million** Stock Offering by Global Surgical AI Healthcare!

AI will prevent cancer by detecting it early

EXECUTIVE SUMMARY & BUSINESS PLAN

Global Surgical AI Healthcare

Mark Kembel

12505 NE 116th St, A35

Kirkland, Washington

Email: markkembel@gmail.com

Direct Line 1.425.403.5468

WhatsApp: 1.425-324-8264

Send investment payment to the address above in Kirkland and we will process it and send you your stock certificate.

Global Surgical AI Healthcare is a C corporation and used to be AI Online Developer +. The new name reflects the change of our mission to now provide technical knowledge of surgical operations. Website **GlobalVisionProAI.com**.

Mark Kembel: A Visionary Leader in AI Medical Healthcare

Mark Kembel is a pioneering entrepreneur and seasoned AI technology expert whose career bridges the worlds of artificial intelligence and AI Medical Healthcare. With a passion for innovation and a dedication to democratizing complex technologies, Mark has built a reputation as a forward-thinking leader driving real-world impact in the AI spaces.

Today, Mark is the founder Global Surgical AI Healthcare Inc., The company provides a diverse portfolio of AI Healthcare plans to develop Vision Pro designed operation programs for the physicians to do their operations with expert training and precision work.

With a career rooted in innovation, Mark Kembel continues to inspire a new generation of learners and technologists, proving that with the right guidance, anyone can harness the power of AI.

Mark's background in technology and being an AI Engineer is being used to work with developers on the AI Healthcare Project. His knowledge and partners in the development section will do the work on Cancer Research and the rest of the offerings Global Surgical AI Healthcare provides. He will bring in a CEO that has an RN with surgical medical background to help with the knowledge to get through the FDA trials and work with the Board on managing the Nurses that will sell our programs. He will also help with explaining to investors and hospitals for the medical knowledge that we provide.

Research Summary

I'm developing a groundbreaking AI-powered software integrated with augmented reality (AR) glasses to transform cancer detection and surgical procedures. This innovative technology enables real-time identification of cancerous tissues, assisting surgeons during operations and reducing reliance on external monitors. By overlaying critical imaging data directly into the surgeon's field of view, it enhances precision and efficiency in the operating room.

Our AI system is designed to analyze various medical imaging modalities, including CT scans, MRIs, and X-rays, to detect multiple cancer types such as breast, lung, prostate, colorectal, pancreatic, skin (including basal cell carcinoma, squamous cell carcinoma, and melanoma), and brain cancers.

All these surgeries listed in the middle of the page are on our list for developing a program for using Vision Pro in surgeries to start with.

Email the following: markkembel@gmail.com

Business Mission

To supply hospitals with Vision Pro glasses for doing operations with precision in the following areas. Our focus on getting doctors the best support to doing these surgeries.

Total Subscription Value: \$1.2M USD Bundle deal \$1 Million USD

3 Vision Pro glasses included in price for each program if you pay the Assigned Subscription Cost. When calling Identify your country. For pricing outside the United States, Europe or Middle East email markkembel@gmail.com for prices.

SUBSCRIPTION COSTS		
	SURGERY	COST
	NEUROSURGERY	\$200.000
	ORTHOPEDICS	\$190.000
	OPHTHALMOLOGY	\$180.000
	CARDIOTHORACIC SU	\$170.000
	VASCULAR SURGERY	\$160.000
	CANCER	\$100.000
	GASTROINTESTINAL	\$100.000
	UROLOGY	\$100.000



We plan to make the physician's job easier by using the glasses to display the different signs for monitoring the progress of the surgery.

Plan for 2026 Sales & Development

We will setup pretrial FDA programs in 2026 in several hospitals to get a jump to getting to the final stage. Global Surgical AI Healthcare will hire an FDA expert to manage all trials and to get us certified as soon as possible. Most of our business will be overseas so we will need to get the setup material and trainer available to the hospitals. The Vision Pro can also teach the doctors to go through the surgery on its own without a patient.

We will ask the hospitals which surgery is the most critical for them and start development on the programs in 2026 as well after the first two are done.

It will take 5 months for development of the Orthopedics and Cancer programs. We will market both of them for training once they are finished. The plan is to sell them for half price \$50,000 for Cancer and \$80,000 for Orthopedics. Once we get FDA approval we will offer the hospital the program for surgery for the other half of the price for the full year in 2027.

The market out side of the US we will charge full price once the programs are done. That is where we will make our sales as a priority. Call us to get an idea of the earning power of Vision Pro and the website will be www.GlobalVisionProAI.com come October 10, 2025.

Our plan is to have as many programs as possible ready by 2027 so we can patent the AI code to keep competition out of our market.

Funding Request Option

The Company will sell 600,000 Preferred non-voting stock for \$50.00 per share, a total of \$6,000,000.00, to be used for the following purposes listed in the marketing section. There is no limit to how many shares one person can buy. The company reserves the right to purchase stock first before outsiders buy the stock. The company also gets the right to transfer stock to its books if the stockholder wishes to sell. If the stockholder dies the transfer of stock will go to the beneficiaries. The stock must be held for at least two years. All stock to be purchased in U.S. dollars from foreign investors. Minimum investment \$2,500.00 or 250 preferred shares. The Mark Kembel, CEO has just been awarded 250,000 shares of Common stock bring his shares to 1,000,000 Common Voting shares.

Common shares unissued are 2,000,000. Number of Common shares created are 3,000,000. The company created 1,000,000 Preferred non-voting stock share total.

To get financial projections for sales just email us. But here's the more exhilarating part: I invite you to be part of our journey. We're opening an opportunity for \$6 Million in funding. These funds will be meticulously allocated to amplify our outreach (advertising), hire an elite sales force, and onboard a seasoned Marketing Manager who'd helm the ship with their expertise and vision. Other financing avenues are also on the table, and we're flexible in discussions.

Advantages

Problem:

Modern surgery is a triumph of medicine, but it still suffers from:

Limited intraoperative visibility of hidden structures

Reliance on multiple external monitors, forcing surgeons to look away from the patient

Training bottlenecks due to limited access to real surgeries

Inconsistent precision between surgeons, leading to varied patient outcomes

These inefficiencies cost hospitals millions annually and contribute to longer recovery times, surgical complications, and preventable readmissions.

Solution:

The Apple Vision Pro Surgical Platform turns the OR into an intelligent, augmented reality environment where:

Surgeons see 3D anatomical overlays, real-time imaging, and AI-assisted guidance directly in their field of view

Pre-op scans and MRI data are layered on the patient's actual anatomy with sub-millimeter accuracy

Voice, hand, and eye controls keep the surgeon sterile and focused—
no keyboard or mouse needed

A “digital twin” of each procedure is captured for instant playback,
training, and quality control

Remote experts can join live surgeries virtually—anywhere in the
world—cutting consultation delays from days to seconds

Mark Kembel: A Visionary Leader in AI Medical Healthcare

Mark Kembel is a pioneering entrepreneur and seasoned technology expert whose career bridges the worlds of artificial intelligence and AI Medical Healthcare. With a passion for innovation and a dedication to democratizing complex technologies, Mark has built a reputation as a forward-thinking leader driving real-world impact in the AI spaces.

Today, Mark is the founder and CEO of **AI Online Developer Plus, Inc.**, a cutting-edge platform offering practical, industry-relevant training in artificial intelligence, data science, and software development as well as leading a technology consulting firm that is a leader in Medical AI. The company provides a diverse portfolio of AI Healthcare plans to develop Vision Pro designed operation programs for the physicians to do their operations with precision work.

With a career rooted in innovation, Mark Kembel continues to inspire a new generation of learners and technologists, proving that with the right guidance, anyone can harness the power of AI. Visit <https://Globalvisionproai.com/> to get more information on Mark's AI Programs.

Funding Option

The Company will sell 120,000 Preferred non-voting stock for \$50.00 per share, a total of \$6,000,000.00, to be used for the following purposes listed in the marketing section. There is no limit to how many shares one person can buy. The company reserves the right to purchase stock first before outsiders buy the stock. The company also gets the right to transfer stock to its books if the stockholder wishes to sell. If the stockholder dies the transfer of stock will go to the beneficiaries. The stock must be held for at least two years. All stock to be purchased in U.S. dollars from foreign investors. Minimum investment \$2,500.00 or 50 preferred shares. The Mark Kembel, CEO has just been awarded 250,000 shares of Common stock bring his shares to 1,000,000 Common Voting shares. Common shares unissued are 2,000,000. Number of Common shares created are 3,000,000. The company created 1,000,000 Preferred non-voting stock share total.

To get financial projections for sales just email us. But here's the more exhilarating part: I invite you to be part of our journey. We're opening an opportunity for \$6 Million in funding. These funds will be meticulously allocated to amplify our outreach (advertising), hire an elite sales force, and onboard a seasoned Marketing Manager who'd helm the ship with their expertise and vision. Other financing avenues are also on the table, and we're flexible in discussions.